Categories
Anticancer Drugs Oncology Palonosetron Pharmacology Physiotherapy

Palonosetron and Oral Aprepitant

In this article we will discuss Palonosetron and Oral Aprepitant

In this article, we will discuss Palonosetron and Oral Aprepitant. So, let’s get started.

Palonosetron and Oral Aprepitant

In an interaction study in healthy subjects where a single 0.25 mg intravenous dose of
palonosetron HCl was administered on day 1 and oral aprepitant for 3 days (125 mg/80
mg/80 mg), the pharmacokinetics of palonosetron were not significantly altered (AUC: no change, Cmax: 15% increase).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.